Mitral Valve Disease Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment Type (Repair, Replacement, Cardiac Resynchronization Therapy, Therapeutics), By Indication (Stenosis, Prolapse, Regurgitation), By End-User (Hospitals, Ambulatory Surgical Centers, Others), By Region & Competition, 2020-2030F

Market Overview

Global Mitral Valve Disease Market was valued at USD 3.25 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.85% through 2030. The Global Mitral Valve Disease (MVD) Market is a rapidly expanding segment within the cardiovascular devices and treatments sector. Mitral valve diseases, including conditions such as mitral valve regurgitation (MR) and mitral valve stenosis (MS), affect millions of individuals globally, creating a significant market opportunity. Key growth drivers include an aging population, a rising prevalence of cardiovascular diseases, ongoing advancements in medical technologies, and a growing preference for minimally invasive treatment options.

This market is poised for robust growth, fueled by innovations in diagnostic and therapeutic technologies, alongside a heightened focus on minimally invasive procedures. With a sharp emphasis on improving patient outcomes, expanding access to treatment, and integrating new technologies, the MVD market is positioned to experience substantial growth in the coming years. The increasing awareness of mitral valve disease, particularly in aging populations, is further contributing to the demand for effective and accessible treatment solutions. As the prevalence of MVD continues to rise, it will remain a critical factor driving market expansion, creating new opportunities for industry stakeholders to capitalize on advancements that enhance both treatment efficacy and patient care.

Key Market Drivers

Rising Prevalence of Mitral Valve Disease (MVD)

The rising prevalence of mitral valve disease (MVD) is one of the most significant drivers propelling the growth of the global mitral valve disease market. As MVD becomes increasingly common worldwide, the demand for diagnostic services, treatment options, and healthcare infrastructure tailored to this condition intensifies. In addition to aging, modern lifestyle factors are contributing to the higher incidence of MVD. Obesity, hypertension, diabetes, and smoking are risk factors that significantly increase the likelihood of developing cardiovascular diseases, including MVD. As these lifestyle-related conditions become more prevalent globally, particularly in emerging economies, there is a corresponding rise in the number of patients suffering from MVD. This growing incidence drives the need for more frequent diagnoses, interventions, and long-term management strategies. As of 2022, approximately 1 in 8 individuals globally were living with obesity. The prevalence of adult obesity has more than doubled since 1990, while adolescent obesity has seen a fourfold increase over the same period. In total, 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Notably, 43% of adults worldwide were overweight, and 16% were affected by obesity in 2022.

Childhood obesity remains a significant concern, with 37 million children under the age of 5 being classified as overweight. Additionally, hypertension is a growing global issue, with an estimated 1.28 billion adults aged 30 to 79 suffering from the condition. The majority (approximately two-thirds) of these individuals reside in low- and middle-income countries. Alarmingly, nearly half (46%) of adults with hypertension remain unaware of their condition, and only 42% of those diagnosed with hypertension receive proper treatment. Even more concerning, only 21% of adults with hypertension have the condition under control.

Hypertension remains one of the leading causes of premature death globally, highlighting the urgent need for effective management. One of the key global targets for noncommunicable diseases is to reduce the prevalence of hypertension by 33% between 2010 and 2030, presenting both a challenge and a strategic opportunity for businesses and healthcare systems focused on prevention, diagnosis, and treatment.

As life expectancy continues to rise, the risk of developing MVD increases. The survival of individuals with cardiovascular conditions is improving due to medical advancements, but many of these individuals continue to live with the condition for extended periods. Consequently, there is a larger patient base that requires ongoing monitoring, treatment, and interventions for mitral valve diseases. This prolonged life expectancy significantly contributes to the sustained demand for healthcare services and innovative treatments for MVD, thereby driving market growth. Global life expectancy is projected to rise from 73.6 years in 2022 to 78.1 years by 2050, reflecting a 4.5-year increase. Notably, the most significant gains in life expectancy are expected in countries with currently lower life expectancies, helping to narrow global disparities. This trend presents both opportunities and challenges for businesses in healthcare, insurance, and consumer goods sectors as they adjust to the growing demands of an aging population, particularly in emerging markets. Mitral valve disease is a significant subset of the broader category of cardiovascular diseases. Cardiovascular diseases (CVDs) are the leading cause of death globally, and MVD is a critical component of this problem. As the global burden of CVDs continues to rise, particularly in developing countries where urbanization and sedentary lifestyles are on the rise, MVD is becoming an increasingly common cause of heart failure and other serious complications. This expanding burden puts additional pressure on healthcare systems to provide more diagnostic, treatment, and management solutions for MVD, further boosting market demand. Cardiovascular diseases (CVDs) remain the primary cause of global mortality. In 2021, out of the 20.5 million deaths attributed to CVDs, roughly 80% occurred in low- and middle-income countries. This disparity highlights significant market opportunities for businesses in the healthcare and pharmaceutical sectors, particularly in these regions, where there is an urgent need for targeted cardiovascular prevention, treatment, and management solutions.

Growing Healthcare Expenditure in Emerging Markets

The growing healthcare expenditure in emerging markets is a key driver for the growth of the global mitral valve disease (MVD) market. As these markets experience rapid economic growth, urbanization, and improvements in healthcare infrastructure, there is an increasing demand for advanced medical treatments, diagnostics, and specialized healthcare services. This shift in healthcare spending directly impacts the demand for treatments for MVD, leading to a significant expansion of the market. Healthcare expenditure in emerging economies is expected to increase significantly, eventually aligning more closely with the levels seen in developed nations. Currently, the U.S. allocates 19% of its GDP to healthcare, while European countries invest around 12%. In contrast, countries like India and those in Southeast Asia currently spend between 3% and 5% of their GDP on healthcare. This gap presents a substantial growth opportunity for businesses in the healthcare sector, as rising income levels and shifting government priorities in emerging markets drive increased investment in health infrastructure and services. Emerging markets, particularly in regions such as Asia-Pacific, Latin America, and the Middle East, are seeing significant economic growth, leading to higher disposable incomes and improved standards of living. As these economies grow, individuals have more purchasing power and are better able to afford healthcare services, including those for specialized conditions such as mitral valve disease. This rise in income levels enables patients to access both diagnostic services and advanced medical treatments, thus driving the demand for MVD care. With healthcare becoming more accessible, there is a growing patient base seeking treatment for cardiovascular diseases, including MVD.

As emerging markets grow economically, they are also investing heavily in healthcare infrastructure. Governments, along with private investors, are building more hospitals, diagnostic centers, and specialized cardiac care facilities. This development is critical in addressing the rising burden of cardiovascular diseases, including MVD. With state-of-the-art equipment and the availability of highly skilled healthcare professionals, these markets are able to provide advanced diagnostic tools (such as echocardiograms, MRIs, and CT scans) and cutting-edge treatments like minimally invasive valve repair and replacement procedures. The improvement of healthcare infrastructure in these markets is a major factor in expanding the access and availability of MVD treatment options. Governments in emerging markets are recognizing the importance of addressing chronic diseases like MVD, and as a result, they are allocating larger portions of their budgets to healthcare initiatives. This includes funding for the prevention, diagnosis, and treatment of heart diseases. In many emerging economies, national health insurance programs are expanding to cover a broader range of services, including heart valve treatments. With this increased government spending, more patients are able to access advanced treatments that were previously unavailable or unaffordable. Such government-backed initiatives are crucial in driving the adoption of MVD-related interventions and therapies, thereby expanding the market for these solutions.

Download Free Sample Report

Key Market Challenges

High Treatment Costs

One of the primary challenges facing the growth of the Global Mitral Valve Disease Market is the high cost associated with diagnosis and treatment. Mitral valve diseases often require complex surgical interventions or implantation of prosthetic valves, which can be prohibitively expensive for many patients and healthcare systems.

Mitral valve surgeries, whether traditional open-heart procedures or minimally invasive techniques like transcatheter mitral valve repair (TMVR), involve substantial costs. These expenses encompass surgeon fees, operating room charges, and the cost of prosthetic valves.

Recovery and post-operative care for mitral valve disease patients can be extensive, driving up healthcare costs. Frequent follow-up appointments, medications, and cardiac rehabilitation programs all contribute to the financial burden. In some regions, insurance coverage for mitral valve disease treatments may be limited or inadequate. This lack of comprehensive coverage can deter patients from seeking timely medical attention and hinder the market's growth.

Limited Access to Advanced Healthcare Services

Access to advanced healthcare services, especially in rural or underserved areas, remains a significant challenge in mitigating mitral valve diseases. Disparities in healthcare infrastructure and resources can limit the timely diagnosis and treatment of patients.

Rural or remote regions often lack the specialized medical facilities and expert healthcare providers required for diagnosing and treating mitral valve diseases. Patients in these areas may face extended travel times to reach appropriate healthcare centers.

High out-of-pocket expenses, coupled with limited insurance coverage, can create financial barriers that hinder access to quality care. This is particularly problematic for individuals with limited financial resources. Shortages of skilled cardiac surgeons and cardiologists in some areas can result in longer wait times for treatments and surgeries. Delayed interventions can lead to worsened patient outcomes.

Regulatory and Compliance Challenges

The Global Mitral Valve Disease Market is subject to stringent regulatory requirements and compliance standards imposed by health authorities. Navigating these regulations, obtaining necessary approvals, and ensuring compliance can pose significant challenges for manufacturers and healthcare institutions.

Bringing new mitral valve disease treatment options to the market often requires conducting extensive clinical trials to demonstrate safety and efficacy. Meeting these rigorous trial standards can be time-consuming and expensive.

Gaining regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) can be a lengthy and complex process. Delays in approvals can slow down the introduction of innovative treatments. Manufacturers and healthcare providers must adhere to strict quality control and compliance standards. Ensuring that products and procedures meet these standards can be resource-intensive and demanding.

Key Market Trends

Minimally Invasive Procedures on the Rise

One prominent trend in the Global Mitral Valve Disease Market is the increasing adoption of minimally invasive procedures for the diagnosis and treatment of mitral valve diseases. Traditionally, open-heart surgery was the standard approach for mitral valve repair or replacement. However, advances in medical technology have led to the development of less invasive alternatives, such as transcatheter mitral valve repair (TMVR) and transcatheter mitral valve replacement (TMVR).

Minimally invasive procedures offer several advantages, including smaller incisions, reduced pain, shorter hospital stays, and quicker recovery times. Patients are increasingly opting for these less invasive options, contributing to their popularity.

The availability of minimally invasive techniques has expanded the range of patients who can undergo mitral valve interventions. High-risk or elderly patients who may not be suitable candidates for open-heart surgery can now benefit from these innovative procedures. Healthcare professionals are gaining expertise in performing minimally invasive mitral valve procedures, further boosting their adoption. This trend is likely to continue as more specialists become proficient in these techniques.

Advancements in Implantable Devices

Another significant trend in the Global Mitral Valve Disease Market is the continuous advancement of implantable devices used for mitral valve repair and replacement. Prosthetic valves and devices are undergoing constant innovation to improve their performance and durability.

Recent developments have led to prosthetic valves with longer lifespans. This is crucial, as it reduces the need for repeat surgeries and improves the overall quality of life for patients.

Manufacturers are increasingly offering customizable prosthetic valves to better match individual patient anatomy. This customization enhances the effectiveness of valve replacement and minimizes complications. Implantable devices are now being made with biocompatible materials that reduce the risk of adverse reactions or complications. These materials improve the long-term performance of the devices.

Telemedicine and Remote Monitoring

In recent years, the adoption of telemedicine and remote monitoring solutions in the field of cardiology, including mitral valve disease management, has gained momentum. This trend has been further accelerated by the COVID-19 pandemic, which highlighted the importance of remote healthcare delivery.

Telemedicine allows patients to consult with healthcare professionals from the comfort of their homes, overcoming geographical barriers and ensuring that even those in remote areas can access specialized care.

Remote monitoring solutions enable continuous tracking of patients' cardiac health. This real-time data allows for early detection of complications and adjustments to treatment plans, enhancing patient outcomes. Telemedicine can result in cost savings for both patients and healthcare systems. Fewer in-person visits and hospitalizations lead to reduced healthcare expenditures, making care more affordable and sustainable.

Segmental Insights

Treatment Type Insights

Based on the category of Treatment Type, The repair segment is emerging as the fastest-growing category in the global Mitral Valve Disease (MVD) market, driven by advancements in minimally invasive technologies, the increasing preference for less invasive procedures, and the growing demand for improved patient outcomes. This trend reflects a shift in treatment preferences, as both patients and healthcare providers prioritize techniques that offer shorter recovery times, fewer complications, and better long-term results. there has been a significant rise in minimally invasive mitral valve repair procedures, such as Transcatheter Mitral Valve Repair (TMVR). These techniques, which involve smaller incisions and shorter recovery times compared to traditional open-heart surgery, are particularly appealing to elderly and high-risk patients who may not be suitable candidates for more invasive surgeries. The development and adoption of these advanced techniques are increasing the appeal of mitral valve repair over replacement, making it a primary choice for both healthcare providers and patients, driving the growth of the segment.

Mitral valve repair procedures, especially those performed via minimally invasive methods, tend to offer superior long-term outcomes compared to valve replacement. Studies have shown that valve repair can maintain the patient’s native anatomy and heart function, reducing the risk of complications such as blood clots, infection, and the need for lifelong anticoagulation therapy, which is often associated with mechanical valve replacements. These superior outcomes are driving the demand for repair procedures, especially as patients and healthcare providers seek to avoid the risks associated with valve replacement surgeries. These factors are expected to drive the growth of this segment.

Indication Insight

Based on the category of Indication, the regurgitation segment emerged as the dominant segment in the global market for Mitral Valve Disease in 2024. Mitral valve regurgitation is the most common indication within the realm of mitral valve disease. This condition occurs when the mitral valve does not close tightly, leading to the backward flow of blood into the left atrium during each heartbeat. As individuals age, the risk of developing mitral valve regurgitation increases. Age-related changes in the structure and function of the mitral valve can lead to regurgitation.

MVR often occurs as a secondary condition in individuals with other heart conditions, such as coronary artery disease, heart attacks, and cardiomyopathy. Certain lifestyle factors, including smoking, obesity, and a sedentary lifestyle, can contribute to the development of MVR. These risk factors are prevalent in many parts of the world. Mitral valve regurgitation exists along a spectrum, with varying degrees of severity. MVR can range from mild, where the regurgitation is minimal and may not require immediate intervention, to severe, where the regurgitation significantly impairs cardiac function and warrants prompt treatment. The ability to intervene at different stages of MVR provides a broad scope for healthcare providers to offer timely and appropriate treatments, including surgical repair or replacement.

Recent advances in medical technology and diagnostic tools have improved the accuracy of diagnosing MVR and expanded the treatment options available for patients, Echocardiography, including 3D and transesophageal echocardiography, allows for precise assessment of the mitral valve, enabling early detection and characterization of regurgitation. The field of cardiac surgery has witnessed the development of innovative procedures for treating MVR, such as minimally invasive approaches like robotic-assisted surgery and transcatheter mitral valve repair (TMVR). Tailoring treatment strategies to the severity of MVR and the patient's overall health allows for personalized care plans that optimize outcomes.

Download Free Sample Report

Regional Insights

North America emerged as the largest market in the global Mitral Valve Disease market in 2024, holding the largest market share in terms of value. North America, particularly the United States, boasts one of the most sophisticated healthcare infrastructures globally, with access to cutting-edge medical technologies and highly skilled healthcare professionals. The region leads in the adoption of advanced diagnostic tools such as echocardiography, CT scans, and MRI technologies, which enable early and accurate detection of mitral valve diseases. Additionally, North American hospitals are equipped with state-of-the-art facilities for minimally invasive surgeries, including Transcatheter Mitral Valve Repair (TMVR) and MitraClip procedures. The rapid adoption and availability of these advanced technologies make the region a primary market for innovative treatments in the MVD space.

The prevalence of cardiovascular diseases, including MVD, is notably high in North America due to several factors such as an aging population, widespread obesity, and lifestyle-related risk factors (e.g., poor diet, sedentary lifestyle, smoking). As a result, the demand for treatments for MVD is particularly strong. In the United States, heart disease remains the leading cause of death, with a significant proportion of these cases linked to valvular diseases like mitral valve regurgitation. This growing burden of cardiovascular diseases fuels the demand for MVD-related diagnostic services, therapies, and surgical interventions, making North America the largest market for MVD treatments.

Recent Developments

• In November 2024, Cytokinetics, Incorporated and Bayer have announced a collaboration and licensing agreement for the exclusive development and commercialization of aficamten in Japan. This partnership will focus on treating patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM), with Cytokinetics retaining certain reserved development rights. Aficamten is a next-generation cardiac myosin inhibitor, aimed at offering a potential treatment option for HCM patients.
• In June 2024, Foldax, Inc., a pioneer in the development of innovative polymer-based heart valves, has announced promising 30-day outcomes from a prospective, multicenter, single-arm clinical trial of its TRIA™ mitral surgical heart valve with LifePolymer™ technology, conducted in India. At the 30-day mark post-surgery, the TRIA valve demonstrated strong safety profiles and favorable hemodynamic performance, aligning with the established benchmarks for heart valve devices. These positive results were shared at the New York Valves, The Structural Heart Summit 2024 by Dr. Isaac George, Surgical Director of the Heart Valve Center at Columbia University.
• In January 2024, CardioMech, a medical device startup, has secured USD13 million in funding to accelerate the development and validation of its flagship device, designed to address degenerative mitral valve regurgitation. The catheter-based device aims to provide a streamlined, direct procedure for patients who are candidates for open-heart surgery, as well as those deemed eligible for surgical intervention.
• In September 2023, Abbott completes acquisition of Bigfoot Biomedical, a privately held company that develops and commercializes automated insulin delivery systems. The acquisition is expected to accelerate Abbott's efforts to develop personalized, connected solutions for people with diabetes.
• In September 2023, Zydus Lifesciences Limited (including its subsidiaries and affiliates, collectively referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for its Erythromycin Tablets USP, available in 250 mg and 500 mg dosages (reference listed drug: Erythromycin Tablets USP, 250 mg and 500 mg).

Key Market Players

• Corcym UK Limited
• Abbott Laboratories Inc
• Zydus Lifesciences Limited
• Medtronic plc
• Edwards Lifesciences Corporation
• Affluent Medical SA
• ShockWave Medical, Inc.
• Valcare Medical
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Mitral Valve Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Mitral Valve Disease Market, By Treatment Type:

o   Repair

o   Replacement

o   Cardiac Resynchronization Therapy

o   Therapeutics

• Mitral Valve Disease Market, By Indication:

o   Stenosis

o   Prolapse

o   Regurgitation

• Mitral Valve Disease Market, By End-User:

o   Hospitals

o   Ambulatory Surgical Centers

o   Others

• Mitral Valve Disease Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mitral Valve Disease Market.

Available Customizations:

Global Mitral Valve Disease market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Mitral Valve Disease Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com